Genetics of Dementia (original) (raw)

Abstract

Neurodegenerative adult-onset dementias are complex and multifactorial diseases that are most commonly caused by environmental, genetic, or mixed environmental and genetic factors. Regarding the genetic causes, a variety of phenotypes may present. This article reviews several of the genetic risk factors for the most common dementias encountered in neurology. Practical implications of genetic testing and pharmacogenomic considerations for clinical practice are also discussed.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (55)

  1. Robakis NK. Alzheimer's disease: new light on etiology and management. Mt. Sinai J Med 2010;77(1):1Y2.
  2. Priller C, Bauer T, Mitteregger G, et al. Synapse formation and function is modulated by the amyloid precursor protein. J Neurosci 2006;26(27):7212Y7221.
  3. Bettens K, Sleegers K, Van Broeckhoven C. Current status on Alzheimer disease molecular genetics: from past, to present, to future. Hum Mol Genet 2010;19(R1):R4YR11.
  4. Brouwers N, Sleegers K, Van Broeckhoven C. Molecular genetics of Alzheimer's disease: an update. Ann Med 2008;40(8):562Y583.
  5. Sleegers K, Lambert JC, Bertram L, et al. The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects. Trends Genet 2010;26(2):84Y93.
  6. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261(5123): 921Y923.
  7. Matthews BR. Alzheimer disease update. Continuum Lifelong Learning Neurol 2010; 16(2):15Y30.
  8. Roses AD. An inherited variable poly-T repeat genotype in TOMM40 in Alzheimer disease. Arch Neurol 2010;67(5):536Y541.
  9. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994;7(2):180Y184.
  10. Martins IJ, Berger T, Sharman MJ, et al. Cholesterol metabolism and transport in the pathogenesis of Alzheimer's disease. J Neurochem 2009;111(6):1275Y1308.
  11. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009;63(3):287Y303.
  12. Zhou W, Xu D, Peng X, et al. Meta-analysis of APOE4 allele and outcome after traumatic brain injury. J Neurotrauma 2008;25(4):279Y290.
  13. St George-Hyslop PH. Genetics of dementia. Continuum Lifelong Learning Neurol 2008; 14(2):29Y48.
  14. Ertekin-Taner N. Genetics of Alzheimer disease in the pre-and post-GWAS era. Alzheimers Res Ther 2010;2(1):3.
  15. Bertram L, Tanzi RE. Alzheimer disease: new light on an old CLU. Nat Rev Neurol 2010;6(1):11Y13.
  16. Rogaeva E, Meng Y, Lee JH, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 2007;39(2):168Y177.
  17. Lambert JC, Heath S, Even G, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009; 41(10):1094Y1099.
  18. Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009; 41(10):1088Y1093.
  19. Nuutinen T, Suuronen T, Kauppinen A, Salminen A. Clusterin: a forgotten player in Alzheimer's disease. Brain Res Rev 2009; 61(2):89Y104.
  20. Neary D, Snowden J, Mann D. Frontotemporal dementia. Lancet Neurol 2005;4(11):771Y780.
  21. Rohrer JD, Guerreiro R, Vandrovcova J, et al. The heritability and genetics of frontotemporal lobar degeneration. Neurology 2009;73(18):1451Y1456.
  22. van Swieten JC, Heutink P. Mutations in progranulin (GRN) within the spectrum of clinical and pathological phenotypes of frontotemporal dementia. Lancet Neurol 2008;7(10):965Y974.
  23. Neumann M, Tolnay M, Mackenzie IR. The molecular basis of frontotemporal dementia. Expert Rev Mol Med 2009;11:e23.
  24. Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006; 442(7105):916Y919.
  25. Finch N, Baker M, Crook R, et al. Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain 2009;132(pt 3):583Y591.
  26. Skibinski G, Parkinson NJ, Brown JM, et al. Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat Genet 2005;37(8):806Y808.
  27. Kimonis VE, Watts GD. Autosomal dominant inclusion body myopathy, Paget disease of bone, and frontotemporal dementia. Alzheimer Dis Assoc Disord 2005;19(suppl 1): S44YS47.
  28. Talbot K, Ansorge O. Recent advances in the genetics of amyotrophic lateral sclerosis and frontotemporal dementia: common pathways in neurodegenerative disease. Hum Mol Genet 2006;15(spec no 2): R182YR187.
  29. Yener GG, Rosen HJ, Papatriantafyllou J. Frontotemporal degeneration. Continuum Lifelong Learning Neurol 2010; 16(2):191Y211.
  30. Lomen-Hoerth C. Amyotrophic lateral sclerosis from bench to bedside. Semin Neurol 2008;28(2):205Y211.
  31. Levy JR, Sumner CJ, Caviston JP, et al. A motor neuron disease-associated mutation in p150Glued perturbs dynactin function and induces protein aggregation. J Cell Biol 2006;172(5):733Y745.
  32. Momeni P, Schymick J, Jain S, et al. Analysis of IFT74 as a candidate gene for chromosome 9p-linked ALS-FTD. BMC Neurol 2006;6:44.
  33. Known point variations in human prion gene coding region. Published 2000. www.mad-cow.org/prion\_point\_ mutations.html. Accessed April 17, 2010.
  34. Mead S. Prion disease genetics. Eur J Hum Genet 2006;14(3):273Y281.
  35. Zarranz JJ, Digon A, Atares B, et al. Phenotypic variability in familial prion diseases due to the D178N mutation. J Neurol Neurosurg Psychiatry. 2005;76(11):1491Y1496.
  36. Finckh U, Mu ¨ller-Thomsen T, Mann U, et al. High prevalence of pathogenic mutations in patients with early-onset dementia detected by sequence analyses of four different genes. Am J Hum Genet 2000;66(1):110Y117.
  37. Offit K. Genomic profiles for disease risk: predictive or premature? JAMA 2008;299(11):1353Y1355.
  38. Alzheimer Association. Recommendations to update diagnostic criteria. Published 2010. Available at www.alz.org/research/ diagnostic_criteria/overview.asp.
  39. Tierney MC, Szalai JP, Snow WG, et al. A prospective study of the clinical utility of ApoE genotype in the prediction of outcome in patients with memory impairment. Neurology 1996;46(1):149Y154.
  40. Green RC, Roberts JS, Cupples LA, et al. Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med 2009;361(3):245Y254.
  41. Rogaeva EA, Fafel KC, Song YQ, et al. Screening for PS1 mutations in a referral-based series of AD cases: 21 novel mutations. Neurology 2001;57(4):621Y625.
  42. Poirier J, Delisle MC, Quirion R, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci USA 1995;92(26):12260Y12264.
  43. Risner ME, Saunders AM, Altman JF, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 2006;6(4):246Y254.
  44. Lane R, Feldman HH, Meyer J, et al. Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. Pharmacogenet Genomics 2008;18(4):289Y298.
  45. Strobel G. Chicago: Bapineuzumab's phase 2VWas the data better than the spin? 2008. http://www.alzforum.org/new/detail. asp?id=1894.
  46. Quinn JF, Raman R, Thomas RG, et al. A clinical trial of docosahexanoic acid (DHA) for the treatment of Alzheimer's disease. Alzheimers Dement 2009; 5(4):84.
  47. Reger MA, Henderson ST, Hale C, et al. Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. Neurobiol Aging 2004;25(3):311Y314.
  48. Henderson ST, Vogel JL, Barr LJ, et al. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond) 2009;6:31.
  49. Haag MD, Hofman A, Koudstaal PJ, et al. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity: the Rotterdam Study. J Neurol Neurosurg Psychiatry 2009;80(1):13Y17.
  50. Li G, Shofer JB, Rhew IC, et al. Age-varying association between statin use and incident Alzheimer's disease. J Am Geriatr Soc 2010;58(7):1311Y1317.
  51. Li NC, Lee A, Whitmer RA, et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010;340:b5465.
  52. Mishra S, Palanivelu K. The effect of curcumin (turmeric) on Alzheimer's disease: an overview. Ann Indian Acad Neurol 2008;11(1):13Y19.
  53. Yurko-Mauro K, McCarthy D, Rom D, et al. MIDAS Investigators. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement 2010;6(6):456Y464.
  54. Whalley LJ, Deary IJ, Starr JM, et al. n-3 Fatty acid erythrocyte membrane content, APOE (4, and cognitive variation: an observational follow-up study in late adulthood. Am J Clin Nutr 2008;87(2): 449Y454.
  55. Cacabelos R. Pharmacogenomics in Alzheimer's disease. In: Cohen N, ed. Pharmacogenomics and personalized medicine. New York, NY: Humana Press; 2008:317Y368.